Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + hepatitis B vaccine + inactivated poliovirus vaccine + Haemophilus influenzae type b conjugate vaccine
- Development stage
- Unknown
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This is a **hexavalent combination vaccine** designed for active immunization in infants and young children against six serious diseases: diphtheria, tetanus (lockjaw), pertussis (whooping cough), hepatitis B, poliomyelitis, and invasive disease caused by Haemophilus influenzae type b. Each component antigen (diphtheria toxoid, tetanus toxoid, acellular pertussis antigens, recombinant hepatitis B surface antigen, inactivated poliovirus types 1/2/3, Hib polysaccharide conjugated to protein) stimulates the immune system to produce specific protective antibodies against the respective pathogens, thereby providing immunity and preventing disease. The combination enables multiple protections with a single injection, improving immunization coverage and compliance. It is approved for use in infants as part of national childhood immunization schedules. The vaccine does not treat these diseases; it is purely preventive.
- Brand names
- VaxelisHexaximInfanrix hexa
- Other names
- diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and Haemophilus B conjugate and hepatitis B vaccineDTaP-HepB-IPV-Hibhexavalent vaccineDTPa-HBV-IPV/HibDTaP-IPV-HepB-Hib
02
Targets
HBsAg (Hepatitis B surface antigen)Diphtheria toxinPV (Poliovirus (Types 1, 2, and 3))
Beyond the preview
Go deeper on diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + hepatitis B vaccine + inactivated poliovirus vaccine + Haemophilus influenzae type b conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + hepatitis B vaccine + inactivated poliovirus vaccine + Haemophilus influenzae type b conjugate vaccine.